Article
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
Molecular cancer therapeutics - 2 Mar 2026
Starrett Jacqueline H, Allen Eric L, Neal Melissa, Iyer Samhita, Ye Qing, Hudkins Robert L, Degaonkar Viraj, Lihou Christine, Swanson Ronald V, Boni Valentina, Fuentes-Antrás Jesús, Pobel Cedric, Loriot Yohann, Zalutskaya Alena, Goluboff Erik
Abstract excerpt
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)-altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)-a rationally designed selective FGFR3 inhibitor-was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.